Skip to main content
Clinical Trials/NCT01750710
NCT01750710
Completed
Not Applicable

Correlation Between Clinical and Electrophysiological Phenotypes in a Population of Patients With Neuropathy Charcot-Marie-Tooth Disease Type 1A

University Hospital, Clermont-Ferrand1 site in 1 country37 target enrollmentDecember 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Charcot-Marie-Tooth Type 1A Neuropathy
Sponsor
University Hospital, Clermont-Ferrand
Enrollment
37
Locations
1
Primary Endpoint
axonal loss
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

This exploratory cross-sectional study proposes, firstly, to objectify in a population of Charcot-Marie-Tooth disease type 1A (CMT 1A)if there is a correlation between the recording of electrical parameters and upper limb muscle strength of the thigh and in a second step, to seek a relationship between the measured parameters.

Detailed Description

Patients suffering from CMT 1A neuropathy will be invited to go through a series of tests such as: * Electromyography * Isokinetic test * Podiatric assessment * Functional evaluations: Hand dexterity, limbs muscles strength * Quality of life assessment with questionnaires

Registry
clinicaltrials.gov
Start Date
December 2012
End Date
April 28, 2016
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
University Hospital, Clermont-Ferrand
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients older than 18 years
  • Diagnosis of Charcot Marie Tooth disease, type 1A confirmed by molecular biology (duplication 17.p11.2)
  • Listening and written French
  • Agreement after written information, clear and honest about the purpose of the study, the nature of the tests and their possible side effects or bothersome.
  • Strength of the quadriceps superior to 2/5 MMT MRC

Exclusion Criteria

  • Presence of other neurological comorbidity
  • Presence of coronary artery disease unstabilized
  • Peripheral neuropathy of other causes: diabetes, monoclonal gammopathy, malignancy, solid cancer, systemic autoimmune disease (lupus, Sjögren's disease, Wegener sarcoidosis ...), infectious disease (viral hepatitis, HIV ...), drugs known to be responsible for iatrogenic neuropathy.
  • Gait trouble of other origin
  • Patients unable to give their consent.
  • Intellectual deficit that does not allow to comply with tests

Outcomes

Primary Outcomes

axonal loss

Time Frame: at day 1

Secondary Outcomes

  • Depression(at day 1)
  • spatial and temporal parameters of walking(at day 1)
  • Barometric stabilometric podo-static scores(at day 1)
  • Quality of life(at day 1)
  • Muscle strength(at day 1)
  • Functional scores(at day 1)
  • Hand testing(at day 1)
  • Fatigue(at day 1)

Study Sites (1)

Loading locations...

Similar Trials